Form D · Biotechnology
Neogene Therapeutics, Inc.
New York, NY · CIK 0001757966
Offering snapshot reported Sep 14, 2020 · SEC filing
- Reported sold
- $110M Offering amount: $110M
- Investors reported
- 63 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 2, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 14, 2020 | Initial | $110,000,049 | No comparison | 63 | SEC filing |
| May 23, 2019 | Initial | $15,000,000 | No comparison | 42 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-375460
Source: Form D, filed Sep 14, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Fei Chen | Director |
| Franz Humer | Director |
| Rajul Jain | Director |
| Helen Kim | Director |
| Carsten Linnemann, Ph D | Director, Executive, Promoter |
| Rachel Mears | Director |
| Elisa Petris | Director |
| Antonius N.M. Schumacher | Director |
| Caroline Stout | Director |
| David Tanen | Director, Promoter |
| Katherine Wood | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
689 Fifth Avenue 12th Floor
New York, NY, 10022
New York, NY, 10022